[1] |
LI Mingying, ZHANG Xiaoxia, SUN Xiaoli, ZHAO Yan, HE Miao, LI Yanling, DUAN Wei, YANG Ou.
Effect of Sugammadex on Recovery of Patients after Laparoscopic Total Pelvic Floor Reconstruction
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 896-901.
|
[2] |
YU Yong, MA Shouliang, SHENG Yuqin.
Allergic Reactions and Treatment Involving Sodium Dimercaptopropane Sulfate Injection during Copper Chelation for Wilson’s Disease
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 771-775.
|
[3] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[4] |
LIANG Fanglin, CHEN Lingyuan, HU Danli, WEI Lingyun, WEI Tiemeng, ZHANG Faen, WEI Yana.
Immune-Related Adverse Events of Tislelizumab in 120 Patients with Hepatocellular Carcinoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 659-663.
|
[5] |
YE Ling, LIU Xiaoying, DANG Xuefei, LI Xuelian, LI Gang.
Research Progress in Drugs for Brain Metastases from Advanced Breast Cancer
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 714-720.
|
[6] |
WANG Fengxin, LI Lei, HUANG Xurui, ZHAO Yun, LING Ruby, YANG Yang, LIANG Changhao, ZENG Yuntao, ZHENG Yingjun, TANG Yuanchen, LIU Jiatao, WANG Chengxiang, WEN Tiancai, LI Ping.
Efficacy and Safety of Danshen Decoction in Treatment of Coronary Heart Disease
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 575-579.
|
[7] |
NI Wenqi, ZHU Feng, ZHOU Shuang, CUI Yimin.
Research Progress in Drug-Induced Hypotension
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 475-480.
|
[8] |
CHENG Weineng, PAN Qiuna, YANG Jing, FENG Qiang, TANG Xiaomeng, LIANG Yue.
Retrospective Analysis of 763 Cases of Drug Eruptions
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 104-108.
|
[9] |
ZHANG Jing, ZHANG Kai, YI Zhanmiao.
Efficacy and safety of salvianolic acid preparations for adjuvant therapy on related diseases of coronary heart disease, angina and cerebral infarction: a systematic review
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 910-915.
|
[10] |
LIU Qian, LI Bo, SHU Xinyang.
Lanqin oral liquid combined with antibacterial drugs for the treatment of acute tonsillitis: a systematic review and Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 916-920.
|
[11] |
XIA Lanfang, LI Keli, WANG Lei, LI Yan, WANG Huaqing.
Impact of comparator selection on signal detection in adverse events following immunization in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 798-804.
|
[12] |
GAO Xu, PENG Jin’e, FAN Zibo, ZHANG Wei.
Systematic evaluation of clinical features and prognostic outcomes of rifampicin-induced hemolytic anemia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 671-676.
|
[13] |
ZHANG Jian, ZHANG Lingli, LI Xin.
Immune-related adverse events of tirelizumab in 424 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 435-439.
|
[14] |
JIANG Wenshuo, YANG Li.
Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
|
[15] |
ZHANG Lei, LYU Jian, XIE Yanming.
Efficacy and safety of Houpupaiqi Mixture in the treatment of postoperative lieus: a Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 799-806.
|